Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,289 across all filing types
Latest filing 2022-04-26 Governance Information
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
安图生物对外担保管理制度（2022年4月修订）
Governance Information Classification · 95% confidence The document is titled '郑州安图生物工程股份有限公司 对外担保管理制度' which translates to 'Zhengzhou Antu Bioengineering Co., Ltd. External Guarantee Management System'. The content is a detailed internal policy document outlining the rules, procedures, responsibilities, and risk management related to the company's external guarantees (担保). It includes governance, decision-making authority, contract requirements, risk controls, disclosure obligations, and responsibilities of various departments and personnel. There is no indication that this is a financial report, earnings release, or regulatory filing. It is not an announcement or a brief summary but a comprehensive internal governance document. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Legal Proceedings. It is a governance-related document detailing internal rules and procedures. Therefore, the most appropriate classification is Governance Information (CGR). The document length (over 10,000 characters) and detailed content support this classification with high confidence.
2022-04-26 Chinese
安图生物董事会议事规则（2022年4月修订）
Governance Information Classification · 95% confidence The document is titled '郑州安图生物工程股份有限公司 董事会议事规则' which translates to 'Zhengzhou Antu Bioengineering Co., Ltd. Board Meeting Rules'. The content details the rules and procedures for the board of directors' meetings, including meeting types, proposal procedures, voting, and record-keeping. It references relevant laws and regulations governing board operations but does not contain financial data, earnings, or report disclosures. It is a governance document outlining internal board meeting rules and practices rather than a report or announcement of financial results or corporate actions. Therefore, the document fits the category of Governance Information (CGR). The document length (5765 characters) supports it being a full governance report rather than a brief announcement or notice.
2022-04-26 Chinese
安图生物独立董事关于公司第四届董事会第四次会议相关事项的独立意见
AGM Information Classification · 95% confidence The document is an independent opinion from the independent directors of Zhengzhou Antu Bioengineering Co., Ltd. regarding several proposals to be submitted to the company's 2021 annual general meeting (AGM). The proposals include profit distribution, use of raised funds, appointment of auditors, senior management remuneration, internal control evaluation, and insurance for directors and senior management. The document is not the AGM materials themselves but an independent opinion on matters to be voted on at the AGM. It is relatively short (1452 characters) and does not contain financial statements or detailed financial data. Therefore, it is best classified as AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including independent directors' opinions on AGM agenda items.
2022-04-26 Chinese
安图生物2021年度非经营性资金占用及其他关联资金往来情况的专项说明
Regulatory Filings
2022-04-26 Chinese
安图生物信息披露事务管理制度（2022年4月修订）
Governance Information Classification · 95% confidence The document is titled '信息披露管理制度' which translates to 'Information Disclosure Management System' and is a detailed internal policy document of Zhengzhou Antu Bioengineering Co., Ltd. It outlines the company's procedures, responsibilities, and regulatory compliance requirements for information disclosure, including definitions of periodic reports, temporary reports, disclosure obligations, confidentiality, and internal controls. It does not contain actual financial data, earnings, or audit results, nor is it an announcement or summary of a report. Instead, it is a governance and compliance document detailing the company's internal rules and procedures for information disclosure. Therefore, it fits best under Governance Information (CGR).
2022-04-26 Chinese
安图生物投资者关系管理制度（2022年4月修订）
Governance Information Classification · 95% confidence The document is titled '郑州安图生物工程股份有限公司 投资者关系管理制度' which translates to 'Zhengzhou Antu Bioengineering Co., Ltd. Investor Relations Management System'. It is a detailed policy document outlining the company's investor relations management principles, activities, responsibilities, and organizational structure. It does not contain financial statements, audit results, earnings data, or any reportable financial performance metrics. It is not an announcement of a report but a governance or procedural document related to investor relations. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is over 5,000 characters and is substantive, not a brief announcement or certification. Therefore, the classification is CGR with high confidence.
2022-04-26 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.